• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs

Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs

by Elena Iemma | Apr 20, 2021

In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

by Annie De Groot | Jan 22, 2020

Kruiswijk et al 2020 – In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance
The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

The iVAX Toolkit: An in silico platform for epitope discovery with applications to human and animal vaccine design

by Annie De Groot | Oct 23, 2019

EpiVax_ISV_iVAX_23Oct19
Pigs immunized with heterologous EPITOPE-prime, INACT-boost swine flu vaccine have fewer lung lesions and lower body temperature after challenge

Pigs immunized with heterologous EPITOPE-prime, INACT-boost swine flu vaccine have fewer lung lesions and lower body temperature after challenge

by Annie De Groot | Oct 23, 2019

ISVConference_primeboost_IAV_v8_16Oct2019
In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

by Annie De Groot | Aug 2, 2019

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models
« Older Entries
Next Entries »

Recent Posts

  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • EpiVax Seminars in Tokyo
  • The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
  • March of the Teenage B Cells
  • EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

Recent Comments

No comments to show.

Join our newsletter

 Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CSO, Dr. Annie De Groot. 

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline